Banafsheh Kashani, MD: Uterine Fibroids and the Importance of FDA Approvals


Banafsheh Kashani, MD, discusses the current treatment path for patients with uterine fibroids, along with recent FDA approvals.

Banafsheh Kashani, MD

Banafsheh Kashani, MD

Uterine fibroids are small muscle cell tumors inside or outside the uterus. And the condition is extremely common.

The best way to diagnose fibroids is through an ultrasound of the pelvis to see the location of the fibroid. Another way is through an MRI to get a more 3D view of the uterus.

Fibroids can cause a variety of issues for women, including heavy menstrual cycles, infertility, pain, and pressure. Because of all the problems fibroids can cause, it is important to have a proper treatment plan in place.

Typically, fibroids are removed surgically. If a tumor is found, historically the solution is to try to take it out. There are various surgeries 1 can undergo for removal, Banafsheh Kashani, MD, a board-certified OB/GYN at Eden Fertility Centers, said in a recent interview with HCPLive®.

“But surgery has its risks,” she said.

Pain and recovery, undergoing anesthesia, and having to take time off work are all caveats to having a surgical procedure. So, many people are trying to find alternative treatments through pills or injectables.

Even such options could lead to risks, though.

Many women started using leuprolide (Lupron) as an injection which puts women into temporary menopause. But it has its risks and cannot be used long-term.

There are, however, new and emerging therapies coming to the market to address the issue. The US Food and Drug Administration (FDA) has focused on bringing safe and effective treatments for the condition.

To learn more about recent FDA approvals for uterine fibroids and treating the condition, watch the full clip featuring Kashani below.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Riha Bhatt, MD: Mimickers and Concurrent Diseases in Pediatric IBD
Elizabeth Spencer, MD: Precision Medicine in Pediatric IBD
Anita Clayton, MD: Zuranolone for Postpartum Depression
Mikkael Sekeres, MD:
Lynn Malec, MD: FVIII Therapy Improves Levels in Pediatric Patients with Hemophilia A
© 2024 MJH Life Sciences

All rights reserved.